/
RSS Feed
HOWARD MAYER, Pfizer Global Research, New London CT
MARK WAINBERG, McGill University, Montreal
Abstract Number: 104aLB, 104bLB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-28, 2007
In a population of treatment-experienced HIV-infected subjects, maraviroc plus optimised background antiretroviral therapy provided significantly superior virologic control and increases in CD4 cell counts compared with placebo plus optimized background therapy. There were no clinically relevant differences in the safety profiles between the maraviroc and the placebo treatment groups. These drugs do not attack the virus itself but rather block host cells’ CCR5 cell surface cytokine receptors that HIV interacts with to gain entry into the cell. At the Los Angeles conference Dan Keller heard about the studies from Howard Mayer and Mark Wainberg.
[audio:https://www.audiomedica.com/podcasting/global_health/070313howard_mayer.mp3] In a population of treatment-experienced HIV-infected subjects, maraviroc plus optimised background antiretroviral therapy provided significantly superior virologic control and increases in CD4 cell counts compared with placebo plus optimized background therapy. There were no clinically relevant differences in the safety profiles between the maraviroc and the placebo treatment groups. These drugs do not attack the virus itself but rather block host cells’ CCR5 cell surface cytokine receptors that HIV interacts with to gain entry into the cell. At the Los Angeles conference Dan Keller heard about the studies from Howard Mayer and Mark Wainberg.
